JP2023536904A - 補体が媒介する疾患を有する対象における炎症性サイトカインおよび疲労 - Google Patents

補体が媒介する疾患を有する対象における炎症性サイトカインおよび疲労 Download PDF

Info

Publication number
JP2023536904A
JP2023536904A JP2023507563A JP2023507563A JP2023536904A JP 2023536904 A JP2023536904 A JP 2023536904A JP 2023507563 A JP2023507563 A JP 2023507563A JP 2023507563 A JP2023507563 A JP 2023507563A JP 2023536904 A JP2023536904 A JP 2023536904A
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
acid sequence
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536904A5 (enExample
Inventor
ハイメ・モラレス・アリアス
ウィリアム・イー・ホッブス
マイケル・ジェイ・シュトレク
パリジャ・エス・パテル
Original Assignee
バイオベラティブ・ユーエスエイ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオベラティブ・ユーエスエイ・インコーポレイテッド filed Critical バイオベラティブ・ユーエスエイ・インコーポレイテッド
Publication of JP2023536904A publication Critical patent/JP2023536904A/ja
Publication of JP2023536904A5 publication Critical patent/JP2023536904A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/306—Chronic fatigue syndrome
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023507563A 2020-08-06 2021-08-05 補体が媒介する疾患を有する対象における炎症性サイトカインおよび疲労 Pending JP2023536904A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063062243P 2020-08-06 2020-08-06
US63/062,243 2020-08-06
PCT/US2021/044761 WO2022031978A1 (en) 2020-08-06 2021-08-05 Inflammatory cytokines and fatigue in subject with a complement mediated disease

Publications (2)

Publication Number Publication Date
JP2023536904A true JP2023536904A (ja) 2023-08-30
JP2023536904A5 JP2023536904A5 (enExample) 2024-12-16

Family

ID=77750323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507563A Pending JP2023536904A (ja) 2020-08-06 2021-08-05 補体が媒介する疾患を有する対象における炎症性サイトカインおよび疲労

Country Status (11)

Country Link
US (1) US20230357433A1 (enExample)
EP (1) EP4193153A1 (enExample)
JP (1) JP2023536904A (enExample)
KR (1) KR20230044312A (enExample)
CN (1) CN116724236A (enExample)
AU (1) AU2021320870A1 (enExample)
BR (1) BR112023001942A2 (enExample)
CA (1) CA3187866A1 (enExample)
IL (1) IL300376A (enExample)
MX (1) MX2023001492A (enExample)
WO (1) WO2022031978A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
CN110300520B (zh) 2016-10-12 2022-10-04 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
WO2022212645A1 (en) * 2021-03-31 2022-10-06 Bioverativ Usa Inc. Reducing surgery-associated hemolysis in cold agglutinin disease patients
US20240117021A1 (en) * 2022-06-15 2024-04-11 Bioverativ Usa Inc. Anti-complement c1s antibody formulation
CA3260415A1 (en) * 2022-06-24 2023-12-28 Bioverativ Usa Inc. METHODS OF TREATMENT FOR COMPLEMENT-MEDICATED DISEASES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020502996A (ja) * 2016-10-12 2020-01-30 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗Ｃ１ｓ抗体およびその使用方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
EP2997045A4 (en) * 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
CA2981321A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
MX2017016835A (es) * 2015-06-26 2018-08-01 Bioverativ Usa Inc Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios.
US11464810B2 (en) * 2016-08-25 2022-10-11 California Institute Of Technology Ascaroside treatment of eosinophilic esophagitis
CR20190468A (es) 2017-03-14 2019-12-17 Bioverativ Usa Inc Métodos para tratar enfermedades y trastornos mediados por completo
EP3774892A4 (en) * 2018-04-13 2022-02-16 Chugai Seiyaku Kabushiki Kaisha ANTI-COMPLEMENT COMPONENT ANTIBODIES AND METHODS OF USE
JP7499760B2 (ja) * 2018-11-02 2024-06-14 アネクソン，インコーポレーテッド 脳損傷を治療するための組成物及び方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020502996A (ja) * 2016-10-12 2020-01-30 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗Ｃ１ｓ抗体およびその使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEXANDER ROTH ET AL.: "Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results", BLOOD, vol. Vol.134, Supplement 2, JPN6025030001, 2019, pages 2 - 1, ISSN: 0005834258 *
BOGNA GRYGIEL-GORNIAK ET AL.: "Fatigue and interleukin-6 - a multi-faceted relationship", REUMATOLOGIA, vol. 53, no. 4, JPN6026012787, 2015, pages 207 - 212, ISSN: 0005834260 *
SIGBJORN BERENTSEN: "New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia", FRONTIERS IN IMMUNOLOGY, vol. Vol.11, Article number: 590, JPN6025030000, April 2020 (2020-04-01), pages 1 - 13, ISSN: 0005834259 *

Also Published As

Publication number Publication date
EP4193153A1 (en) 2023-06-14
KR20230044312A (ko) 2023-04-03
US20230357433A1 (en) 2023-11-09
WO2022031978A1 (en) 2022-02-10
IL300376A (en) 2023-04-01
CA3187866A1 (en) 2022-02-10
MX2023001492A (es) 2023-03-08
AU2021320870A1 (en) 2023-04-06
CN116724236A (zh) 2023-09-08
BR112023001942A2 (pt) 2023-02-28

Similar Documents

Publication Publication Date Title
US20230357433A1 (en) Inflammatory cytokines and fatigue in subject with a complement mediated disease
JP7293122B2 (ja) 補体が媒介する疾患および障害を処置するための方法
US8624002B2 (en) Prostaglandin E2 binding proteins and uses thereof
KR101540126B1 (ko) 보체-관련 안질환의 예방 및 치료
KR20200018498A (ko) 항-bcma 중쇄-단독 항체
KR20210077725A (ko) 항-cd38 항체의 피하 투여를 제공하는 방법
CN108348600A (zh) 治疗自身免疫病症和同种免疫病症的方法
JP2021524839A (ja) 抗ｐｃｓｋ９抗体を含む製剤およびその使用
US20240025978A1 (en) Methods for treating complement-mediated diseases
US20240052062A1 (en) Reducing surgery-associated hemolysis in cold agglutinin disease patients
JP2025512032A (ja) Ｐｄ－１抗体を含有する安定した高濃度アルギニン製剤及びその使用方法
JP2024503432A (ja) 抗ｃｄ３８抗体及び抗ｃｄ３８抗体の使用
JP2025519612A (ja) Ｉｇｆ１ｒ抗体
CA2585977C (en) Remedy for endometriosis
WO2026080698A1 (en) Methods of treatment of gastrointestinal inflammatory diseases using α4β7 binding antibody and tl1a binding antibody
CN120282798A (zh) 用于降低需要实体器官移植的受试者中的同种抗体水平的方法
WO2026053130A1 (en) Anti-btla antibodies and uses of the same
HK40075201B (zh) 稳定的水性抗-tfpi抗体制剂
HK40022920A (en) Methods for treating complement-mediated diseases and disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260407